⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21723036 | 0.64 | ALDH1A1 (0.32) | — | |
| SCHEMBL9905505 | 0.62 | — | — | |
| SCHEMBL21722751 | 0.62 | CA2 (0.40) | — | |
| SCHEMBL3295020 | 0.58 | FFAR4 (0.34) | — | |
| SCHEMBL23012647 | 0.57 | CA2 (0.45) | — | |
| SCHEMBL8247736 | 0.57 | — | — | |
| SCHEMBL13273096 | 0.57 | — | — | |
| SCHEMBL1795530 | 0.57 | — | — | |
| SCHEMBL2573898 | 0.57 | HSD17B10 (0.35) | — | |
| Hydrochloric Acid SCHEMBL22532201 | 0.56 | SMN1; SMN2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-118666832-A | Urea compounds and compositions as SMARCA2/BRM atpase inhibitors | 诺华股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2024-08-15 | — | — | US | disclosed |
| CN-112585136-B | Urea compounds and compositions as SMARCA2/BRM atpase inhibitors | 诺华股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2024-04-16 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4219488-A1 | METHOD FOR THE PREPARATION OF UREA COMPOUNDS AS SMARCA2/BRM-ATPASE INHIBITORS | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3837256-B1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM-ATPASE INHIBITORS | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-4081526-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| WO-2021134004-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRODINGER, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| CN-112585136-A | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | 诺华股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020035779-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2020-02-20 | — | — | WO | disclosed |